Quarterly report pursuant to Section 13 or 15(d)

Business (Tables)

v3.20.2
Business (Tables)
3 Months Ended
Sep. 30, 2020
Schedule Of Entities In Control [Abstract]  
Summary of entities in control
The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:
 
    
Principal place
of

business/country
of incorporation
    
Ownership
Fiscal
Year 2020
   
Ownership
Fiscal
Year 2019
 
Benitec Biopharma Proprietary Limited (“BBL”)
     Australia        100     —    
Benitec Australia Proprietary Limited
     Australia        100     100
Benitec Limited
     United
Kingdom
 
 
     100     100
Benitec, Inc.
     USA        100     100
Benitec LLC
     USA        100     100
RNAi Therapeutics, Inc.
     USA        100     100
Tacere Therapeutics, Inc.
     USA        100     100